Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20287503 | 0.81 | DGAT1 (0.39) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL2719 | 0.80 | HDAC6 (0.33) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL1259595 | 0.77 | HDAC6 (0.34) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL15137400 | 0.74 | CA14 (0.36) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL28570172 | 0.74 | HDAC6 (0.33) | HDAC6HDAC1HDAC2DGAT1 | |
| SCHEMBL8359852 | 0.74 | HDAC6 (0.33) | HDAC6HDAC1HDAC2DGAT1 | |
| SCHEMBL9978408 | 0.73 | TAS2R38 (0.35) | — | |
| SCHEMBL6512340 | 0.73 | HDAC6 (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL28652589 | 0.73 | HDAC6 (0.37) | HDAC6HDAC1HDAC2DGAT1CA14 | |
| SCHEMBL7024160 | 0.73 | HDAC6 (0.41) | HDAC6HDAC1HDAC2DGAT1CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110156641-B | Synthesis method of substituted guanidine | 西安近代化学研究所 | 2022-06-10 | — | — | CN | claimed |
| WO-2021121068-A1 | MACROMOLECULE FOR PROMOTING INTAKE OF ANTICANCER DRUG, AND COMPOSITION CONTAINING SAME AND USE THEREOF IN PREPARATION OF ANTICANCER DRUG | 南开大学 | 2021-06-24 | — | — | WO | claimed |
| US-20060270628-A1 | Antiinfective 1,2,3-triazole derivatives, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES, INC. | 2006-11-30 | — | — | US | claimed |
| US-6914058-B2 | 1-(p-(thiomorpholino)phenyl)-1,2,3-triazole derivatives | DR. REDDY'S LABORATORIES, LIMITED (IN) | 2005-07-05 | — | — | US | claimed |
| US-20050113347-A1 | NOVEL ANTIBACTERIAL COMPOUNDS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LIMITED | 2005-05-26 | — | — | US | claimed |
| WO-2004101531-A1 | ANTIINFECTIVE 1,2,3-TRIAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-11-25 | — | — | WO | claimed |
| EP-1467977-A1 | NOVEL ANTIBACTERIAL COMPOUNDS:PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | Dr. Reddy's Laboratories Ltd. (IN) | 2004-10-20 | — | — | EP | claimed |
| WO-2003059894-A1 | NOVEL ANTIBACTERIAL COMPOUNDS:PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | DR.REDDY'S LABORATORIES LTD. (IN) | 2003-07-24 | — | — | WO | claimed |
| JP-11279059-A | — | — | None | — | — | JP | disclosed |
| EP-4727948-A1 | ANTIMALARIAL AGENTS | Merck Sharp & Dohme LLC (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4431509-B1 | NOVEL NON-FLUORINATED QUINOLONE COMPOUND AND APPLICATION THEREOF | GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO LTD BAIYUNSHAN PHARMACEUTICAL GENERAL FACTORY (CN) | 2026-01-21 | — | — | EP | disclosed |
| US-12517133-B2 | Macromolecule analysis employing nucleic acid encoding | DF PEPTIDE ACQUISITION LLC | 2026-01-06 | — | — | US | disclosed |
| US-12467049-B2 | Methods and kits using nucleic acid encoding and/or label | DF PEPTIDE ACQUISITION LLC | 2025-11-11 | — | — | US | disclosed |
| US-12320813-B2 | Macromolecule analysis employing nucleic acid encoding | Encodia, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| US-5583146-A | Heterocyclic thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| WO-1996032380-A1 | SUBSTITUTED INDOLYLMETHYLENE-OXINDOLE ANALOGUES AS TYROSINE KINASE INHIBITORS | PHARMACIA & UPJOHN S.P.A. (IT) | 1996-10-17 | — | — | WO | disclosed |
| WO-1996030329-A1 | SUBSTITUTED BENZENE DERIVATIVES USEFUL AS NEURAMINIDASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INCORPORATED (US) | 1996-10-03 | — | — | WO | disclosed |
| WO-1996026933-A1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES, INC. (US) | 1996-09-06 | — | — | WO | disclosed |
| US-5545636-A | TREATING DIABETES MELLITUS | ELI LILLY AND COMPANY (US) | 1996-08-13 | — | — | US | disclosed |
| WO-1995017182-A1 | PROTEIN KINASE C INHIBITORS | ELI LILLY AND COMPANY (US) | 1995-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270628-A1 | Antiinfective 1,2,3-triazole derivatives, process for their preparation and pharmaceutical compositions containing them | IL33, IL5, IL1B | HDAC6 190/4885HDAC1 1208/4885HDAC2 979/4885 |
| US-20050113347-A1 | NOVEL ANTIBACTERIAL COMPOUNDS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CYP3A4, CYP3A43, CYP3A5 | HDAC6 104/4885HDAC1 1286/4885HDAC2 1340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.